Case study: using DCB and DES in polystenotic calcified right SFA in a 75-year old male patient
Boston Scientific is the only company investing in a complete portfolio of drug-eluting therapies, designed to revolutionize the field, as well as ground-breaking pre-clinical and clinical research that are helping define how to better use the technologies. Our commitment is to bring forward innovative therapies that can make a difference in the lives of patients, and our foundation of more than 15 years of design and development has established our clinical leadership.
Renu Virmani, MD
President CV Path Institute
"The longer you have kept the drug in, the better the results are going to be… it's a delicate balance of the total amount of drug you deliver, and for how long you deliver."
DID YOU KNOW
Expert opinion: Drug-Eluting Stent technologies show promise to improve patency rates. Potentially shifting the primary treatment preference away from Balloon-Based treatment.
The Eluvia Drug-Eluting Stent delivers unprecedented results in the SFA through its unique SUSTEND™ drug-delivery
The Ranger Drug Coated balloon has been designed to provide consistent and predictable drug delivery through efficient drug transfer and a strong coating integrity.